305 related articles for article (PubMed ID: 28455944)
21. A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia.
Matsukawa Y; Takai S; Asai K; Kasugai S; Narita H; Komatsu T; Kashiwagi Y; Kato M; Yamamoto T; Gotoh M
Urology; 2015 Sep; 86(3):558-64. PubMed ID: 26189139
[TBL] [Abstract][Full Text] [Related]
22. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
[TBL] [Abstract][Full Text] [Related]
23. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms.
Park YH; Kim TH; Lee SW; Chung BH; Cho JS; Lee JY
Low Urin Tract Symptoms; 2017 May; 9(2):75-81. PubMed ID: 28394492
[TBL] [Abstract][Full Text] [Related]
24. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
25. Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Koh JS; Cho KJ; Kim HS; Kim JC
Int J Clin Pract; 2014 Feb; 68(2):197-202. PubMed ID: 24372906
[TBL] [Abstract][Full Text] [Related]
26. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review.
İlhan B; Erdoğan T; Topinková E; Bahat G;
Eur Geriatr Med; 2023 Aug; 14(4):733-746. PubMed ID: 37245173
[TBL] [Abstract][Full Text] [Related]
27. The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting.
Lee SH; Kim DK; Kim JC; Lee KS; Lee JG; Park CH; Hong SJ; Kim CS; Park JK; Chung BH
Yonsei Med J; 2010 May; 51(3):432-7. PubMed ID: 20376898
[TBL] [Abstract][Full Text] [Related]
28. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
29. Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015.
Kinlaw AC; Jonsson Funk M; Conover MM; Pate V; Markland AD; Wu JM
Med Care; 2018 Feb; 56(2):162-170. PubMed ID: 29287033
[TBL] [Abstract][Full Text] [Related]
30. Positive Association of Male Overactive Bladder Symptoms and Androgen Deprivation: A Nationwide Population-based Cohort Study.
Li JR; Wang SS; Lin CH; DE Groat WC; Cheng CL
Anticancer Res; 2019 Jan; 39(1):305-311. PubMed ID: 30591473
[TBL] [Abstract][Full Text] [Related]
31. What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?
Matsukawa Y; Majima T; Takai S; Funahashi Y; Kato M; Gotoh M
Urol Int; 2019; 103(4):439-443. PubMed ID: 31554005
[TBL] [Abstract][Full Text] [Related]
32. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
33. National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder.
Linder BJ; Gebhart JB; Elliott DS; Van Houten HK; Sangaralingham LR; Habermann EB
Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):e261-e266. PubMed ID: 31157717
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
[TBL] [Abstract][Full Text] [Related]
35. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
Kosilov K; Loparev S; Kuzina I; Shakirova O; Zhuravskaya N; Lobodenko A
Aging Male; 2017 Mar; 20(1):39-44. PubMed ID: 28074677
[TBL] [Abstract][Full Text] [Related]
36. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
37. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
38. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
Nik-Ahd F; Lenore Ackerman A; Anger J
Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
[TBL] [Abstract][Full Text] [Related]
39. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder.
Hagovska M; Svihra J; Macko L; Breza J; Svihra J; Luptak J; Lachvac L
World J Urol; 2024 May; 42(1):287. PubMed ID: 38698269
[TBL] [Abstract][Full Text] [Related]
40. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia.
Welliver C; Feinstein L; Ward JB; Kirkali Z; Martinez-Miller EE; Matlaga BR; McVary K
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):269-273. PubMed ID: 34545201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
